Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs
NCT03312517
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Insomnia
Interventions
DRUG:
Suvorexant 10 mg
DRUG:
Suvorexant 20 mg
DRUG:
Placebo oral capsule
Sponsor
Henry Ford Health System